Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyAlaska Medicaid Beqvez Prior Auth Coverage | OpenP…
    Ask Trek AI about this page
    CurrentAlaska MedicaidPolicy N/A

    Beqvez (fidanacogene elaparvovec-dzkt) — Prior Authorization Criteria

    Customize your policy alerts

    Sign up for all Alaska Medicaid policy alerts

    Know when Alaska Medicaid releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization criteria for the use of Beqvez (fidanacogene elaparvovec-dzkt) in adults with moderate-to-severe hemophilia B under Alaska Medicaid, including approval, denial, monitoring, quantity limits, and duration of approval.

    Policy Summary
    PayerAlaska Medicaid
    PolicyBeqvez (fidanacogene elaparvovec-dzkt) — Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 26, 2024
    Last ReviewJul 26, 2024
    Next Review DateJul 26, 2024
    Key ActionObtain prior authorization by documenting eligibility: age ≥18, Factor IX ≤2% (≤2 IU/dL), >150 prior exposure days, negative AAVRh74var neutralizing antibody test, inhibitor screen ≤0.5 Bethesda units, and hepatic evaluation; note quantity limit of one infusion per lifetime.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥18minimum patient age for approval
    Factor IX ≤2%disease severity required
    Initial 3 moduration of authorization
    1 lifetime

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    quantity limit
    >150required exposure days

    Coverage Criteria for Beqvez (fidanacogene elaparvovec-dzkt)

    Initial approval criteria

    Covered when ALL of the following are met:

    Beqvez approval criteria: 1) Patient is 18 years of age or older; 2) Prescribed by or in consultation with a hematologist; 3) Patient has diagnosis of hemophilia B meeting FDA indications (currently uses Factor IX prophylaxis OR has current/historical life-threatening hemorrhage OR has repeated, serious spontaneous bleeding episodes); 4) Moderate to severe disease defined by factor IX levels ≤2% of normal or <2 IU/dL; 5) >150 previous exposure days to factor IX; 6) No neutralizing antibodies to AAVRh74var per an FDA‑approved test; 7) No history of inhibitors to factor IX and inhibitor screen within two weeks prior to administration negative (≤0.5 Bethesda units); 8) Hepatic ultrasound and elastography performed prior to administrationall conditions required

    FDA indications and listed safety screening required

    Coverage excludes patients with active viral infections or advanced liver disease that increase risk or contraindicate administration. Specifically, patients with active hepatitis B or hepatitis C infection are excluded. Also excluded are patients with uncontrolled HIV infection, those with evidence of advanced hepatic impairment, and patients who have previously received gene therapy for hemophilia B.

    If the patient does not meet all listed approval criteria, prior authorization for Beqvez is not approved and the request will be denied.

    Coding and Clinical Thresholds

    HCPCS / BillingHCPCS
    J3590Unclassified biologics (listed under Quantity Limit / HCPCS in document)
    inv-05: Factor IX level threshold
    Factor IX level threshold≤2% of normal (equivalent to <2 IU/dL)
    Clinical meaningDefines moderate to severe hemophilia B for eligibility
    Approval requirementMust meet this threshold as part of initial approval criteria (see item 4)
    inv-06: Prior exposure days threshold
    Prior exposure days threshold>150 previous exposure days to factor IX
    Approval requirementDocumentation of >150 prior exposure days is required for initial approval (see item 5)
    Clinical rationale

    Provider Requirements, Documentation, and Denial Triggers

    Prior Authorization

    Prior authorization, one-infusion lifetime limit, initial approval 3 months

    Prior authorization is required for Beqvez; requests must meet the listed approval criteria. Quantity is limited to one infusion per lifetime. Initial approval is limited to 3 months; no reauthorization will be approved.

    • HCPCS: J3590
    Step Therapy

    Required treatment history per FDA indications

    Patient must meet the FDA-indication treatment history: currently use Factor IX prophylaxis OR have current/historical life‑threatening hemorrhage OR have repeated, serious spontaneous bleeding episodes.

    Background

    Beqvez (fidanacogene elaparvovec-dzkt) is an adeno-associated virus (AAV) vector–based, single-administration gene therapy indicated for adults with moderate-to-severe hemophilia B to reduce bleeding and the need for factor IX replacement. Candidate selection requires careful screening for viral infections and hepatic function prior to administration.

    Definitions

    inv-12: Definition — Factor IX level ≤2% of normal or <2 IU/dL
    Definition: Moderate to severe hemophilia BFactor IX level ≤2% of normal (equivalent to <2 IU/dL)
    ContextUsed as the disease-severity threshold in the approval criteria (item 4)
    Measurement unitsPercent of normal activity or international units per deciliter (IU/dL)
    inv-13: Definition — >150 previous exposure days to factor IX
    Definition: Prior exposure days>150 previous exposure days to factor IX
    ContextRequired threshold for eligibility and listed as item 5 in the approval criteria
    Documentation
    Policy Summary
    PayerAlaska Medicaid
    PolicyBeqvez (fidanacogene elaparvovec-dzkt) — Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 26, 2024
    Last ReviewJul 26, 2024
    Next Review DateJul 26, 2024
    Key ActionObtain prior authorization by documenting eligibility: age ≥18, Factor IX ≤2% (≤2 IU/dL), >150 prior exposure days, negative AAVRh74var neutralizing antibody test, inhibitor screen ≤0.5 Bethesda units, and hepatic evaluation; note quantity limit of one infusion per lifetime.
    SourceLink
    On This Page
    Coverage Criteria for Beqvez (fidanacogene elaparvovec-dzkt)Coding and Clinical ThresholdsProvider Requirements, Documentation, and Denial TriggersBackgroundDefinitions
    Represents substantial prior factor IX exposure necessary for candidate selection
    Documentation Required

    Required clinical documentation and testing

    Provide documentation verifying disease severity, exposure history, antibody/inhibitor testing, and hepatic evaluation prior to administration.

    • Factor IX level ≤2% of normal or <2 IU/dL
    • >150 prior exposure days to factor IX
    • No neutralizing antibodies to AAVRh74var per an FDA‑approved test
    • Inhibitor screen within two weeks prior to administration negative (≤0.5 Bethesda units)
    • Hepatic ultrasound and elastography performed prior to administration
    Denial Risk

    Denial triggers and exclusions

    Deny authorization if the patient fails to meet approval criteria or has listed exclusionary conditions.

    • Active hepatitis B or hepatitis C infection
    • Uncontrolled HIV infection
    • Evidence of advanced hepatic impairment
    • Prior treatment with gene therapy for hemophilia B
    Medical record evidence of prior factor IX exposure days must be provided